CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IND Swift Laboratories Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IND Swift Laboratories Ltd
SCO 850
NAC, Shivalik Enclave,, Manimajra
Phone: +91 1725061850p:+91 1725061850 CHANDIGARH, 160101  India Ticker: INDSWFTLABINDSWFTLAB
Business Summary
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company’s products include APIs and Impurities. The Company offers reference standards and impurities for various APIs under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for quick and reliable supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories. Its products include Clarithromycin, Clarithromycin Coated Granules, Ezetimibe, Pazopanib HCl, Ranolazine, Aripiprazole, Letrozole, and Imatinib Mesylate, others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Navrattan R.Munjal 70 8/10/2022 4/1/1995
Chief Financial Officer GaganAggarwal
President - US Operations VikasNarendra
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Ind Swift Laboratories Ltd.
INDSWFTLAB

General Information
Number of Employees: 47 (As of 3/31/2024)
Outstanding Shares: 59,086,918 (As of 9/30/2024)
Shareholders: 22,438
Stock Exchange: NSE
Fax Number: +91 1722730504


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024